Sort By

  • Newest

  • Newest

  • Oldest

  • Author Name

  • Author Name

  • David Chaplin

  • Drew Meredith

  • Giselle Roux

  • Greg Bright

  • Ishan Dan

  • James Dunn

  • Lachlan Maddock

  • Owen Raszkiewicz

Rhinomed’s nose for opportunity sniffs out COVID

Rhinomed (RNO, 17.5 cents)Market capitalisation: $44 millionThree-year total return: +4.1% a yearAnalysts’ consensus valuation: n/a The Melbourne-based Rhinomed is a specialist in respiratory airway technology: it is a world-leading developer of nasal devices made from ultra-soft medical-grade bio-compatible polymers, that helps the volume of air travelling through the nose. The company has brought to market three kinds of…
James Dunn | 25th Nov 2020 | More
Is your portfolio ready for 2021?

This year’s Sohn Hearts & Minds Conference, an annual one-day event that brings the finance and investment community together, saw a select group of fund managers fund manager share their best stock idea for the year ahead. This year’s recurring theme without doubt was COVID-19. But grief and tragedy aside, COVID-19 has forced us to…
Ishan Dan | 25th Nov 2020 | More
Thinking forward – ASX MedTech leaders

Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…
James Dunn | 7th Oct 2020 | More